Peter Hirth

9.4k total citations · 4 hit papers
37 papers, 4.2k citations indexed

About

Peter Hirth is a scholar working on Molecular Biology, Materials Chemistry and Oncology. According to data from OpenAlex, Peter Hirth has authored 37 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Materials Chemistry and 6 papers in Oncology. Recurrent topics in Peter Hirth's work include Catalytic Processes in Materials Science (8 papers), Melanoma and MAPK Pathways (4 papers) and HER2/EGFR in Cancer Research (4 papers). Peter Hirth is often cited by papers focused on Catalytic Processes in Materials Science (8 papers), Melanoma and MAPK Pathways (4 papers) and HER2/EGFR in Cancer Research (4 papers). Peter Hirth collaborates with scholars based in United States, Germany and Denmark. Peter Hirth's co-authors include Gerald McMahon, Laimute Taraseviciene‐Stewart, Norbert F. Voelkel, Rubin M. Tuder, Johannes Waltenberger, Cho Tang, Yasunori Kasahara, Li Sun, Brian Yeh and Joseph Schlessinger and has published in prestigious journals such as Nature, Science and Journal of Clinical Investigation.

In The Last Decade

Peter Hirth

35 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors

1997 960 citations Moosa Mohammadi, Gerald McMahon et al. Science profile →
Inhibition of VEGF receptors causes lung cell apoptosis and emphysema

2000 862 citations Yasunori Kasahara, Rubin M. Tuder et al. Journal of Clinical Investigation profile →
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

2001 630 citations Laimute Taraseviciene‐Stewart, Yasunori Kasahara et al. profile →
Vemurafenib: the first drug approved for BRAF-mutant cancer

2012 594 citations Gideon Bollag, James Tsai et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Hirth United States	19	2.1k	1.3k	586	485	382	37	4.2k
Akira Saito Japan	33	1.9k 0.9×	814 0.6×	836 1.4×	394 0.8×	491 1.3×	203	4.3k
Hideki Yokoyama Japan	31	2.9k 1.4×	1.3k 1.0×	1.1k 1.9×	124 0.3×	623 1.6×	85	5.2k
Eugenio Erba Italy	39	2.1k 1.0×	609 0.5×	1.3k 2.1×	260 0.5×	168 0.4×	138	4.6k
Christine M. Sorenson United States	45	3.9k 1.9×	404 0.3×	973 1.7×	196 0.4×	533 1.4×	145	7.0k
Antonino Passaniti United States	39	3.6k 1.7×	549 0.4×	1.1k 1.8×	238 0.5×	691 1.8×	85	5.6k
Stefania Mitola Italy	36	2.8k 1.3×	392 0.3×	799 1.4×	149 0.3×	606 1.6×	111	4.9k
Jie Wu United States	48	6.0k 2.9×	734 0.6×	1.8k 3.0×	398 0.8×	783 2.0×	127	8.4k
Roberto Ronca Italy	35	3.0k 1.4×	432 0.3×	882 1.5×	419 0.9×	559 1.5×	116	5.0k
Xuesong Gu United States	34	2.8k 1.3×	472 0.4×	1.0k 1.8×	184 0.4×	247 0.6×	74	4.3k
Lubor Borsig Switzerland	43	3.3k 1.6×	580 0.4×	2.1k 3.6×	497 1.0×	1.2k 3.1×	99	7.1k

Countries citing papers authored by Peter Hirth

Since Specialization

Citations

This map shows the geographic impact of Peter Hirth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hirth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hirth more than expected).

Fields of papers citing papers by Peter Hirth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hirth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hirth. The network helps show where Peter Hirth may publish in the future.

Co-authorship network of co-authors of Peter Hirth

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hirth. A scholar is included among the top collaborators of Peter Hirth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hirth. Peter Hirth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hirth, Peter, Lothar Wieczorek, & P. Scigalla. (2015). Molecular Biology of Erythropoietin. Contributions to nephrology. 38–53. 1 indexed citations

Nielsen, Ove Juul, Martin Egfjord, & Peter Hirth. (2015). Erythropoietin Metabolism in the Isolated Perfused Rat Liver. Contributions to nephrology. 76. 90–97.

Bollag, Gideon, James Tsai, Jiazhong Zhang, et al.. (2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews Drug Discovery. 11(11). 873–886. 594 indexed citations breakdown →

Maus, Wolfgang, Eberhard Jacob, Rolf Brück, & Peter Hirth. (2012). Nachhaltigkeit Verfügbarer Kraftstoffe Eine Fiktion?. MTZ - Motortechnische Zeitschrift. 73(6). 446–454. 2 indexed citations

Maus, Wolfgang, et al.. (2012). The Future of Exhaust Aftertreatment Design for Electrified DriveTrains. MTZ worldwide. 73(1). 18–25. 2 indexed citations

Maus, Wolfgang, Eberhard Jacob, Rolf Brück, & Peter Hirth. (2012). Sustainable Fuel a Fantasy?. MTZ worldwide. 73(6). 4–11. 1 indexed citations

Buchholz, Bjoern, Bernd Klanke, Gunnar Schley, et al.. (2011). The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis. Nephrology Dialysis Transplantation. 26(11). 3458–3465. 39 indexed citations

Tap, William D., Charles Ginther, Giovanni M. Pauletti, et al.. (2010). Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma. Neoplasia. 12(8). 637–IN3. 71 indexed citations

Taraseviciene‐Stewart, Laimute, Lajos Gera, Peter Hirth, et al.. (2002). A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Canadian Journal of Physiology and Pharmacology. 80(4). 269–274. 26 indexed citations

10.

Brück, Rolf, et al.. (2001). Metal Supported Flow-Through Particulate Trap; a Non-Blocking Solution. 23 indexed citations

11.

Kasahara, Yasunori, Rubin M. Tuder, Laimute Taraseviciene‐Stewart, et al.. (2000). Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. Journal of Clinical Investigation. 106(11). 1311–1319. 862 indexed citations breakdown →

12.

Harris, Georgianna, et al.. (1999). A One-Pot, Two-Step Synthesis of Tetrahydro Asterriquinone E. Organic Letters. 1(3). 431–434. 34 indexed citations

13.

Lipson, Kenneth E., Long Pang, L. Julie Huber, et al.. (1998). Inhibition of Platelet-Derived Growth Factor and Epidermal Growth Factor Receptor Signaling Events after Treatment of Cells with Specific Synthetic Inhibitors of Tyrosine Kinase Phosphorylation. Journal of Pharmacology and Experimental Therapeutics. 285(2). 844–852. 42 indexed citations

14.

Mohammadi, Moosa, Gerald McMahon, Li Sun, et al.. (1997). Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors. Science. 276(5314). 955–960. 960 indexed citations breakdown →

15.

Gazit, Aviv, et al.. (1996). Tyrphostins IV—Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorganic & Medicinal Chemistry. 4(8). 1203–1207. 46 indexed citations

16.

Nielsen, Ove Juul, Martin Egfjord, & Peter Hirth. (1990). The metabolism of recombinant erythropoietin in the isolated perfused rat liver. Liver International. 10(6). 343–349. 9 indexed citations

17.

Eckardt, Kai‐Uwe, A. Kurtz, Peter Hirth, et al.. (1988). Evaluation of the stability of human erythropoietin in samples for radioimmunoassay. Journal of Molecular Medicine. 66(6). 241–245. 73 indexed citations

18.

Noegel, Angelika A., Peter Hirth, Rainer Merkl, et al.. (1985). Probing an adhesion mutant of Dictyostelium discoideum with cDNA clones and monoclonal antibodies indicates a specific defect in the contact site A glycoprotein. The EMBO Journal. 4(13B). 3805–3810. 50 indexed citations

19.

Lathe, Richard, Peter Hirth, Michel De Wilde, Nigel Harford, & Jean-Pierre Lecocq. (1980). Cell-free synthesis of enterotoxin of E. coli from a cloned gene. Nature. 284(5755). 473–474. 73 indexed citations

20.

Klein, Albrecht, et al.. (1977). Cell free synthesis of bacteriophage lambda replication proteins. FEBS Letters. 80(2). 275–278. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact